|
Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. |
|
|
Consulting or Advisory Role - Amgen; ARIAD; Daiichi Sankyo; Incyte; Janssen; Novartis; Pfizer; Seagen; Sunesis Pharmaceuticals |
Speakers' Bureau - Celgene; Incyte; Novartis |
Research Funding - Agios; Amgen; Astellas Pharma; Celator; Millennium; Seagen; Takeda |
Other Relationship - GlycoMimetics |
|
|
Consulting or Advisory Role - Amgen; Astex Pharmaceuticals; Daiichi Sankyo |
Research Funding - Astellas Pharma (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Daiichi Sankyo |
Stock and Other Ownership Interests - Daiichi Sankyo, Novartis, Merck |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Employment - Daiichi Sankyo |
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology |
|
|
Employment - Daiichi Sankyo |
Stock and Other Ownership Interests - Daiichi Sankyo |
|
|
Employment - Daiichi Sankyo |
Stock and Other Ownership Interests - Bristol-Myers Squibb; Daiichi Sankyo |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Employment - Daiichi Sankyo |
Stock and Other Ownership Interests - Daiichi Sankyo (I) |
|
|
Employment - Bellerophon Theraeutics (I); Daiichi Sankyo |
Stock and Other Ownership Interests - Bellerophon Theraeutics (I) |
|
|
Employment - Ambit BioSciences; Daiichi Sankyo |
Stock and Other Ownership Interests - Ambit BioSciences |
|
|
Honoraria - Daiichi Sankyo |
Consulting or Advisory Role - Daiichi Sankyo |